BACKGROUND: Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging. DESIGN AND METHODS: From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalassemia major patients who had been receiving one chelator alone for longer than one year. We identified three groups of patients: 24 treated with deferasirox, 42 treated with deferiprone and 89 treated with desferrioxamine. Myocardial iron concentrations were measured by T2* multislice multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images. Liver iron concentrations were measured by T2* multiecho technique. RESULTS: The global heart T2* value was significantly higher in the deferiprone (34 ± 11 ms) than in the deferasirox (21 ± 12 ms) and the desferrioxamine groups (27 ± 11 ms) (P = 0.0001). We found higher left ventricular ejection fractions in the deferiprone and the desferrioxamine versus the deferasirox group (P = 0.010). Liver iron concentration, measured as T2* signal, was significantly lower in the desferrioxamine versus the deferiprone and the deferasirox group (P = 0.004). CONCLUSIONS: The cohort of patients treated with oral deferiprone showed less myocardial iron burden and better global systolic ventricular function compared to the patients treated with oral deferasirox or subcutaneous desferrioxamine.
BACKGROUND: Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia majorpatients by means of quantitative magnetic resonance imaging. DESIGN AND METHODS: From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalassemia majorpatients who had been receiving one chelator alone for longer than one year. We identified three groups of patients: 24 treated with deferasirox, 42 treated with deferiprone and 89 treated with desferrioxamine. Myocardial iron concentrations were measured by T2* multislice multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images. Liver iron concentrations were measured by T2* multiecho technique. RESULTS: The global heart T2* value was significantly higher in the deferiprone (34 ± 11 ms) than in the deferasirox (21 ± 12 ms) and the desferrioxamine groups (27 ± 11 ms) (P = 0.0001). We found higher left ventricular ejection fractions in the deferiprone and the desferrioxamine versus the deferasirox group (P = 0.010). Liver iron concentration, measured as T2* signal, was significantly lower in the desferrioxamine versus the deferiprone and the deferasirox group (P = 0.004). CONCLUSIONS: The cohort of patients treated with oral deferiprone showed less myocardial iron burden and better global systolic ventricular function compared to the patients treated with oral deferasirox or subcutaneous desferrioxamine.
Authors: M A Tanner; R Galanello; C Dessi; M A Westwood; G C Smith; S V Nair; L J Anderson; J M Walker; D J Pennell Journal: J Cardiovasc Magn Reson Date: 2006 Impact factor: 5.364
Authors: Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan Journal: Blood Date: 2005-12-22 Impact factor: 22.113
Authors: Mark A Westwood; Lisa J Anderson; Alicia M Maceira; Farrukh T Shah; Emma Prescott; John B Porter; Beatrix Wonke; J Malcolm Walker; Dudley J Pennell Journal: J Magn Reson Imaging Date: 2007-06 Impact factor: 4.813
Authors: Adriana Ceci; Paola Baiardi; Mariana Catapano; Mariagrazia Felisi; Paolo Cianciulli; Vincenzo De Sanctis; Giovanni Carlo Del Vecchio; Carmelo Magnano; Anna Meo; Aurelio Maggio Journal: Haematologica Date: 2006-09-07 Impact factor: 9.941
Authors: Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen S Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher Journal: Haematologica Date: 2012-01-22 Impact factor: 9.941
Authors: Robert W Grady; Renzo Galanello; Rachel E Randolph; Dorothy A Kleinert; Carlo Dessi; Patricia J Giardina Journal: Haematologica Date: 2012-08-08 Impact factor: 9.941
Authors: Motoi Kobayashi; Tomohiro Suhara; Yuichi Baba; Nicholas K Kawasaki; Jason K Higa; Takashi Matsui Journal: Curr Drug Targets Date: 2018 Impact factor: 3.465